Q-omics provides the consensus-scored PTMAP6 profile across patient tissues and cancer cell-line models. PTMAP6 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PTMAP6 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, PTMAP6 RNA expression shows 6,338 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and BRCA as cancer lineages where PTMAP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTMAP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTMAP6 survival associations across molecular data types. PTMAP6 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTMAP6 RNA expression–survival associations across cancer types. High PTMAP6 expression shows unfavorable associations in STAD, UVM, ESCA, LUAD and UCEC, but favorable associations in BRCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .022). Together, the overview and detailed table identify STAD as the clearest survival context for PTMAP6 RNA expression.
This table summarizes PTMAP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PTMAP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTMAP6 shows lower tumor expression in BRCA and higher tumor expression in LUSC. The BRCA box plot shows higher PTMAP6 RNA expression in normal versus tumor tissue (log2 FC = −0.062, t-test p = .045).
This table shows molecular features associated with PTMAP6 in patient tissues and cancer cell lines. In patient samples, PTMAP6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
